Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies

Graphical abstract

Highlights

- RH5 IgG titers induced by infection are lower than those induced by RH5 vaccination
- Infection- and vaccine-induced RH5 IgGs have different specificity and avidity
- Infection- and vaccine-induced RH5 IgGs interact differently with RH5 mAbs
- Infection-induced IgGs generally do not reduce the activity of vaccine-induced IgGs

Authors

Alexandra C. Willcox, Alex S. Huber, Ababacar Diouf, ..., Simon J. Draper, Carole A. Long, Kazutoyo Miura

Correspondence
kmiura@niaid.nih.gov

In brief

Willcox et al. combine antibodies from malaria-exposed Malians and volunteers who received a reticulocyte-binding protein homolog 5 (RH5) vaccine. In *P. falciparum* growth inhibition assays, infection-induced IgGs generally do not reduce the neutralizing activity of vaccine-induced IgGs. These results suggest that RH5 vaccines will induce effective antibodies in malaria-endemic populations.
Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies

Alexandra C. Willcox,1 Alex S. Huber,1 Ababacar Diouf,1 Jordan R. Barrett,2 Sarah E. Silk,2 David Pulido,2 Lloyd D.W. King,2 Daniel G.W. Alanine,2 Angela M. Minassian,2 Mahamadou Diakite,3 Simon J. Draper,2 Carole A. Long,1 and Kazutoyo Miura1,4,

1Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
2The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, United Kingdom
3Malaria Research and Training Center, Faculty of Medicine, Pharmacy, and Odontostomatologie, University of Sciences, Techniques, and Technologies of Bamako, Bamako 1805, Mali
4Lead contact
*Correspondence: kmiura@niaid.nih.gov
https://doi.org/10.1016/j.xcrm.2021.100326

SUMMARY

Reticulocyte-binding protein homolog 5 (RH5) is a leading Plasmodium falciparum blood-stage vaccine candidate. Another possible candidate, apical membrane antigen 1 (AMA1), was not efficacious in malaria-endemic populations, likely due to pre-existing antimalarial antibodies that interfered with the activity of vaccine-induced AMA1 antibodies, as judged by in vitro growth inhibition assay (GIA). To determine how pre-existing antibodies interact with vaccine-induced RH5 antibodies, we purify total and RH5-specific immunoglobulin Gs (IgGs) from malaria-exposed Malians and malaria-naive RH5 vaccinees. Infection-induced RH5 antibody titers are much lower than those induced by vaccination, and RH5-specific IgGs show differences in the binding site between the two populations. In GIA, Malian polyclonal IgGs show additive or synergistic interactions with RH5 human monoclonal antibodies and overall additive interactions with vaccine-induced polyclonal RH5 IgGs. These results suggest that pre-existing antibodies will interact favorably with vaccine-induced RH5 antibodies, in contrast to AMA1 antibodies. This study supports RH5 vaccine trials in malaria-endemic regions.

INTRODUCTION

Malaria remains one of the biggest threats to global health, with estimates of 228 million clinical cases and 405,000 deaths in 2018. Existing antimalarial control measures, such as insecticide-treated nets, rapid diagnostics, and antimalarial drugs, have reduced malaria cases and deaths dramatically in the last two decades; however, the incidence rate was unchanged between 2014 and 2018. Therefore, it is necessary to supplement existing control measures with new tools, such as vaccines.

Reticulocyte-binding protein homolog 5 (RH5) is one of the leading blood-stage vaccine candidates for Plasmodium falciparum, which is the most lethal Plasmodium species that causes malaria in humans. RH5 is expressed on merozoites and binds to its specific receptor, basigin, on the surface of erythrocytes. RH5 forms a complex with the RH5-interacting protein (Ripr) and cysteine-rich protective antigen (CyRPA), and the formation of this complex is an essential step during parasite invasion. In addition to supportive evidence from longitudinal cohort studies showing associations between anti-RH5 titer and reduced risk of clinical malaria, RH5 vaccination and monoclonal antibody (mAb) inoculation induced protection against P. falciparum in an Aotus monkey challenge model. Polyclonal and monoclonal antibodies raised against RH5 in animals and humans have shown biological activity, as judged by in vitro growth inhibition assay (GIA). In the two Aotus challenge studies, significant positive correlations were observed between in vitro GIA activity of antibodies and in vivo protective effects. Furthermore, a recent phase I/la trial, conducted in a malaria-naive population, demonstrated reduced P. falciparum blood-stage multiplication rates following RH5.1/AS01B vaccination and controlled human malaria infection (CHMI). This in vivo impact on parasite growth significantly correlated with in vitro GIA activity before the challenge.

Apical membrane antigen 1 (AMA1) is one of the best-studied P. falciparum blood-stage vaccine candidates, and multiple human phase I trials and two phase IIb efficacy trials have been conducted (reviewed by Miura). Similar to RH5, AMA1 vaccination elicited GIA-active antibodies in animals and humans and induced protection in Aotus challenge studies. However, in phase IIb trials conducted in target populations, only minor strain-specific protection or no protection was observed. In contrast to RH5, which has relatively conserved amino acid sequences, AMA1 is a polymorphic protein, which at least
partially explains the failure of AMA1-based vaccines in field trials. However, AMA1 antibodies in immunized Malian adults and children demonstrated lower GIA activity than predicted from their AMA1 antibody titers even for homologous parasite strains. Subsequent studies revealed that a mixture of their AMA1 antibody titers even for homologous parasite strains. Subsequent studies revealed that a mixture of their AMA1-specific IgGs and AMA1-specific IgG showed lower GIA activity than the AMA1-specific IgGs tested alone. This effect was termed antibody interference. The detailed mechanism and fine specificity of the interfering IgGs were not identified, but it has been shown that the interference came from malaria-specific IgGs (IgG affinity purified against malaria lystate), and the effect did not simply result from competition for binding to the AMA1 molecule. If antimalarial IgGs induced by natural infection block the activity of other neutralizing vaccine-induced IgGs (e.g., anti-RH5 IgGs) in a target population, this might reduce the efficacy of the vaccine in the field. However, the existence of such an interference effect against antibodies induced by other blood-stage vaccine candidates has not yet been investigated. Given that R5 is currently the main focus of blood-stage vaccine development, it is important to determine the interaction between R5 antibodies induced by vaccination and antimalarial antibodies induced by natural infection. Moreover, in contrast to the interference phenomenon, a study reported a subset of potentiating R5 human mAbs that have no GIA activity on their own but can increase the GIA activity of other neutralizing antibodies by extending the time required for merozoites to invade erythrocytes. This discovery offers an exciting new avenue for increasing the potency of both R5-based and non-R5-based vaccines.

In this study, we purified R5-specific IgGs from malaria-immune Malians, as well as from malaria-naive UK adult vaccinees immunized with a full-length recombinant R5 protein (R5.1) formulated in AS01B adjuvant in a trial designated VAC063, to compare the characteristics of the antibodies. Next, Malian and VAC063 total and R5-specific IgGs were mixed with potentiating mAbs in GIA to elucidate synergistic interactions. Lastly, Malian R5-depleted IgGs were mixed with neutralizing human R5 mAbs and VAC063 polyclonal antibodies (pAbs) to determine the interaction of vaccine-induced antibodies and pre-existing antibodies in GIA. The interactions were generally additive, and a substantial interference effect was not observed, as was seen in the case of AMA1. Thus, this study supports continued trials of R5-based vaccines in malaria-endemic areas.

### RESULTS

#### Epidemiology of IgG responses against RH5-CyRPA-Ripr complex proteins in Mali

The study cohort consisted of 500 individuals aged 1–65 living in the village of Kenieroba, Mali, an area of high malaria transmission with a rainy season from June to December. Serum samples were collected from 405 volunteers at the peak of the malaria transmission season (October). The 405 participants, divided into five age groups with approximately equal numbers of volunteers, are summarized in Table 1. The average number of clinical malaria cases was 1.0 per person per year, with the 5–7 age group experiencing the highest average of 2.0 (Table 1).

The seropositivity of the 405 Malian serum samples was determined by comparing the ELISA optical density (OD) values against sera from 12 U.S. malaria-naive individuals for each protein or P. falciparum FVO parasite lysate (PFVFO). IgG antibodies against PFVFO were undetectable in only 2.7% of all tested sera, underlining the high endemicity of Kenieroba (Figure 1A). By contrast, IgG responses against RH5.1, Ripr, and CyRPA recombinant proteins were detectable in 54.8%, 43.5%, and 19.0% of participants, respectively. The likelihood of a participant having detectable antibodies increased with age for the parasite lysate and all three recombinant proteins (Figure 1A; p < 0.001 for all by chi-square test for trend). The OD values against Ripr and CyRPA were too low to investigate further (Figure S1); therefore, quantitative ELISA units (EUs) were determined only against PFVFO and RH5.1 for seropositive participants. Age positively correlated with PFVFO and RH5.1 EUs in participants under the age of 17 (p < 0.001 for both), but not over the age of 17 (Figure 1B). There was a weak but significant positive correlation between RH5.1 and PFVFO EUs (Figure 1C; p < 0.001). RH5.1 EUs in Malians (only seropositive volunteers) were compared with the peak EUs in volunteers from the VAC063 R5 vaccine trial (Figure 1D) within the same age range (i.e., over the age of 17). The median RH5.1 EU was approximately 170-fold higher in VAC063 volunteers than in the Malian cohort (15,600 and 91 EU, respectively; p < 0.001). P. falciparum infection at the time of sample collection was associated with seropositivity against RH5.1, but among seropositive participants, P. falciparum infection did not associate with higher EU (Figure S2). To determine the biological activity of Malian antibodies, total IgGs were purified from pooled (n = 23) and individual (n = 24, selected based on available volume) Malian sera and tested in GIA. The total IgGs exhibited activity ranging from 0% to 100% inhibition in GIA.

#### Comparison of RH5-specific IgGs from naturally exposed Malians and vaccinated volunteers

To evaluate the characteristics of naturally acquired R5-specific IgGs, we purified R5-specific IgGs from each of the 23 Malian pooled total IgGs. Eight of the pools with relatively high RH5.1 EU yielded R5-specific IgGs of sufficient volume and concentration for further experiments (open symbols in Figure 2).
For comparison, eight total IgG pools were made from the VAC063 vaccine trial, and RH5-specific IgG purification was performed similarly.

Serial dilutions of the five highest-titer VAC063 RH5-specific IgGs were tested in GIA, and there was a sigmoid correlation between RH5.1 EU and %GIA, as shown in a previous human trial (VAC057)\(^1\)7 (Figure 3A). The activity of the VAC063 RH5-specific IgGs was then compared with the activity of the five total IgG pools from which they were purified. On a plot of EU versus %GIA, the overlay of VAC063 RH5-specific and total IgGs suggests that the affinity purification process did not change the functional activity of the antibodies (Figure 3A). The five highest-titer Malian RH5-specific IgGs were tested only at a single high concentration in GIA due to limited volumes (Figure 3A). The highest-titer Malian RH5-specific IgG (3,738 EU) failed to show GIA activity (0%GIA), although both total and RH5-specific VAC063 IgGs tested at the same EU showed ~30%GIA. However, the second-highest-titer Malian RH5-specific IgG (2,856 EU) demonstrated 21%GIA, which was similar to the VAC063 samples. The other 3 Malian RH5-specific IgGs were tested with <800 EU and showed <10%GIA.

We next compared all eight Malian and eight VAC063 RH5-specific IgGs for differences in binding to the RH5 protein at equivalent EUs against RH5.1. The RH5.1 protein was used in previous ELISAs (Figures 1 and 2), to capture RH5-specific IgGs in affinity purification, and for vaccination in the VAC063 trial. The avidity of the Malian RH5-specific IgGs was lower than that of those from the VAC063 trial (p < 0.001; Figure 3B). Next, two truncated versions of the RH5 protein were used in ELISA: RH5\(_{\text{DNL}}\) (RH5 lacking the N terminus and disordered loop) and RH5Nt.17 In the current study, the VAC063 RH5-specific IgGs bound almost equally to RH5\(_{\text{DNL}}\) and RH5Nt (Figures 3C and 3D). Compared with the Malian RH5-specific IgGs, the VAC063 RH5-specific IgGs bound more to RH5\(_{\text{DNL}}\) (p < 0.001; Figure 3C), whereas the Malian RH5-specific IgGs showed more binding to RH5Nt, although there was large variation in the Malian samples (p = 0.050; Figure 3D). The VAC063 RH5-specific IgGs also showed more binding to the reconstituted recombinant RH5-CyRPA-Ripr complex (referred to hereafter as the RH5 complex) than did the Malian RH5-specific IgGs (p < 0.001; Figure 3E).
bodies against several merozoite proteins. The potentiating but they have been shown to increase the activity of other anti-
R5.010, R5.011, and R5.014 are called potentiating mAbs
Potentiating RH5 mAbs boosted GIA activity of VAC063
ELISA units against PfFVO (A) and RH5.1 (B) in purified total IgGs from 47
Malian samples (23 serum pools and 24 individual sera) correlated with the
percentage of inhibition measured by in vitro growth inhibition
%GIA at 10 mg/mL. Spearman r and p values are shown. RH5-specific
IgGs were collected from the eight pooled total IgGs (open circles) with
adequate volume and relatively high RH5.1 EU for the next experiment, seen in
Figure 3.

Potentiating RH5 mAbs boosted GIA activity of VAC063 RH5-specific and total IgGs, but not Malian total IgGs
R5.010, R5.011, and R5.014 are called potentiating mAbs because although they do not exhibit GIA activity on their own, but they have been shown to increase the activity of other antibodies against several merozoite proteins. The potentiating mAbs were individually mixed with the three highest-titer Malian RH5-specific IgGs and with the five highest-titer VAC063 RH5-specific IgGs. The Malian RH5-specific IgGs were tested at the same concentration as used in Figure 3A, and the VAC063 RH5-specific IgGs were diluted to a fixed RH5.1 EU, at which concentration all VAC063 IgGs were expected to give 60% GIA−70%GIA. The original %GIA results are shown in Table S1. The difference between the predicted %GIA (based on the formula for Bliss additivity) and the observed %GIA in a mixture of two antibodies is denoted as Delta from Bliss (DfB; details can be found in the STAR Methods section). Because the potentiating mAbs by themselves do not have activity, in these specific antibody combinations, the predicted %GIA was the same as the %GIA of the RH5-specific IgGs alone, and DfB was calculated as the difference between the %GIA in combination and the %GIA of the RH5-specific IgGs alone. When the synergistic (potentiating) interaction was defined as DfB (from a single assay) being ≥10, the R5.010 and R5.011 mAbs showed a potentiating effect with all five VAC063 RH5-specific IgGs and with two of three Malian RH5-specific IgGs. However, R5.014 demonstrated potentiation with two of five VAC063 and one of three Malian RH5-specific IgGs samples (Figure 4A; Table S1).

The three potentiating mAbs were also tested in combination GIAAs with Malian (n = 22) and VAC063 (n = 24) individual total IgGs, and the original %GIA results are shown in Table S2. Of the 22 Malian individual total IgGs tested, one (5%), six (27%), and three (14%) IgGs showed DfB ≥ 10, whereas 17 (71%), 20 (83%), and 11 (46%) of 24 VAC063 individual total IgGs showed DfB ≥ 10 by R5.010, R5.011, and R5.014, respectively, in the first single experiment (Figure S3). There were positive correlations between %GIA of the total IgG sample by itself and DfB for some combinations, but not for others (Figure S3). To confirm the results, GIA combinations that showed potentiation in this initial screening were repeated twice with different red blood cells (Figure 4B), because we have observed that the activity (i.e., %GIA) of RH5 antibodies can be affected by the batch of red blood cells used in the assay. Because limited amounts of RH5-specific IgGs were available, the combination GIA for Figure 4A was performed only once. However, all other GIA experiments were performed in two independent assays to minimize the batch effect. Unless otherwise described, the %GIA or DfB values reported hereafter are average values from two assays. We considered an additive interaction (i.e., the two antibodies worked independently) as average DfB < ±10, a synergistic (potentiating) interaction as DfB ≥ 10, and an antagonistic interaction as DfB ≤ −10. The ±10 threshold was determined by analyzing variations in the 190 paired combination GIAs performed in this study (i.e., instances in which the same antibody combination was tested in two independent assays). Among these 190 paired GIAs, the absolute values of the 25th, 50th (median), and 75th percentile differences in DfB values between the two assays were 2.2, 5.1, and 9.7, respectively (if there was no error in the assay, the difference in DfB between the two assays would be zero). For Malian individual total IgGs, only zero, three and one IgG showed consistent potentiating interactions (i.e., the average DfB values were ≥10) by R5.010, R5.011, and R5.014, respectively, in the confirmatory GIAs. However, 15, 20, and 11 VAC063 individual total IgGs showed potentiation, respectively (Figure 4B). Altogether, these results indicate that the potentiating mAbs had synergistic effects with RH5 antibodies in the VAC063 samples as expected, but had no or minimal impact on overall GIA activity induced by natural malaria infections in the Malian samples.

Malian polyclonal IgGs interacted additively or synergistically with neutralizing RH5 mAbs and mostly additively with VAC063 total IgGs
In a previous study, mixing Malian AMA1-depleted IgGs with neutralizing AMA1 IgGs from AMA1-vaccinated volunteers resulted in an interference effect in GIAs (i.e., the mixture resulted in lower %GIA than either antibody alone). To explore whether a similar phenomenon exists for RH5, the effect of adding neutralizing vaccine-induced RH5 human mAbs to Malian IgGs depleted of RH5-binding antibodies was assessed in combination GIA. The combination GIAs were performed using RH5-depleted Malian IgGs, instead of Malian total IgGs, to perform a fair comparison with previous studies that used AMA1-depleted IgGs in similar experiments. The neutralizing mAbs (R5.004, R5.008, and R5.016) had GIA activity by themselves. Two independent assays were performed, and the average DfB was calculated for each combination (the original %GIA value for each test condition in each assay can be found in Table S3). Of 23 Malian RH5-depleted IgGs tested, ten, ten, and nine samples showed synergistic effects (i.e., DfB ≥ 10) with R5.004, R5.008, and R5.016, respectively. However, only
One Malian IgG sample mixed with R5.004 showed an antagonistic effect (DfB was -10.9). This mixture condition demonstrated the same %GIA as the activity of R5.004 alone: R5.004 alone had 71%GIA, the Malian RH5-depleted IgG (FT03) alone had 37%GIA, and the mixture had 71%GIA (Table S3). Therefore, this interaction was subadditive (i.e., the mixture of two IgGs demonstrated the same or slightly higher %GIA than either IgG tested alone; see STAR Methods for details). The DfB values of the same Malian RH5-depleted IgG in combination with the three RH5 mAbs correlated significantly (Figure 5A; Spearman rank coefficient $R = 0.61$ with $p < 0.002$ for all three paired tests, i.e., R5.004 versus R5.008, R5.008 versus R5.016, and R5.004 versus R5.016). In other words, Malian RH5-depleted IgGs that had higher DfB with one mAb generally also demonstrated higher DfB with the other two mAbs. The DfB value did not correlate with the GIA activity of the Malian RH5-depleted IgG alone (Figure S4; $p > 0.060$ for the three mAbs).

We next explored the effect of combining RH5 polyclonal antibodies (i.e., VAC063 total IgGs) with 11 selected Malian RH5-depleted IgGs (indicated with arrows in Figure 5A), which represented high ($n = 4$), middle ($n = 3$), and low ($n = 4$) DfB samples in experiments with the neutralizing RH5 mAbs. For this combination GIA, three VAC063 pooled total IgG samples were prepared (UK P09, P10, and P11). All combinations of the 11 Malian RH5-depleted IgGs and VAC063 pooled total IgGs were evaluated in two independent assays (the original %GIA values in each assay are in Table S4). In contrast to the combinations with the neutralizing mAbs, DfB values with the VAC063 pooled total IgGs were generally lower (Figure 5B). Although four of the Malian RH5-depleted IgGs tested in this combination experiment had shown synergistic effects with the neutralizing RH5 mAbs (Figure 5A), only one Malian RH5-depleted IgG showed a slightly synergistic effect with one of the three VAC063 pooled total IgGs tested (DfB was 12 for the mixture of FT15 and VAC063 P11; Figure 5B). However, four, four, and one Malian RH5-depleted IgGs showed antagonistic effects with VAC063 P09, P10, and P11, respectively. Among the antagonistic interactions, most of them were subadditive, with one exception. One Malian RH5-depleted IgG (FT22) showed 45%GIA by itself, and the mixtures of FT22 with the P09, P10, and P11 IgGs showed 36%GIA, 36%GIA, and 43%GIA, respectively, whereas all three VAC063 pooled total IgGs displayed 15%GIA–29%GIA by themselves. Similar to the combination GIA with neutralizing RH5 mAbs (Figure 5A), the levels of DfB across combinations
using the three VAC063 pooled total IgGs were correlated (Figure 5B; Spearman rank coefficients $\geq 0.92$ with $p < 0.001$ for all three paired tests). There was significant correlation between the median DfB values in combinations with the three mAbs and the median values in combinations with the three VAC063 pooled polyclonal total IgGs (Figure 5C; Spearman rank coefficient = 0.68, $p = 0.025$), although the actual DfB values were lower in assays with the VAC063 pooled total IgGs. Finally, combination GIAs were performed using 10 individual Malian total IgGs (without RH5 IgG depletion) that were randomly selected from various age groups and both genders (from 4 to 57 years old, median of 15 years; 5 females and 5 males) and another 3 pools of VAC063 total IgGs in two independent assays (Figure 5D, with the original %GIA values in Table S5). Similar to the combination GIAs with RH5-depleted IgGs, most (8 of 10) of the Malian total IgGs showed additive interactions with all 3 VAC063 pooled IgGs, and the DfB values for combinations with the three VAC063 pooled total IgGs were correlated (Spearman rank coefficients $\geq 0.89$ with $p < 0.001$ for all three paired tests). One Malian total IgG (To09) had synergistic effects with all 3 VAC063 IgGs (DfB of 15.4, 11.9, and 11.9 with UK P12, P13, and P14, respectively), and another Malian total IgG (To03) showed an interference interaction with one of the three VAC063 pooled IgGs (DfB of $-11.4$ for UK P12; To03 alone, UK P12 alone, and the combination demonstrated 13%GIA, 30%GIA, and 28%GIA, respectively). The same To03 IgG had DfB values of $-7.7$ and $-9.1$ with UK P13 and P14, respectively (considered additive interactions by our definition).

**DISCUSSION**

We observed a sharp contrast in the functional activity of infection-induced RH5- and AMA1-specific IgGs, as well as in how vaccine-induced RH5 and AMA1 antibodies interact with pre-existing antimalarial IgGs in individuals living in an endemic area. In the case of AMA1, infection-induced AMA1-specific IgGs from Malians showed the same GIA activity per EU as AMA1 IgGs induced by AMA1 vaccination of malaria-naive adults. However, RH5-specific IgGs from Malians did not consistently show the same GIA activity per EU as RH5 IgGs induced by RH5 vaccination of malaria-naive adults. In addition, when 14 AMA1-depleted IgGs from Malians were incubated with vaccine-induced AMA1 antibodies, all mixtures showed lower parasite inhibition than the vaccine-induced AMA1 antibody alone (a phenomenon termed interference). In contrast, when Malian RH5-depleted IgGs were mixed with VAC063 total IgGs, of 33 conditions tested (11 RH5-depleted Malian IgGs with 3 VAC063 IgGs), the results were as follows: one combination showed a synergistic effect, 23 conditions were additive, 6 combinations were subadditive, and three combinations showed interference. The interference interactions were observed for a single Malian FT22 IgG; the Malian FT22 IgG alone showed 45%GIA, and the combinations with VAC063 P09, P10, and P11 IgGs showed 36%GIA, 36%GIA, and 43%GIA, respectively. Because the difference between 45%GIA and 36%GIA is debatable (within a 10%GIA difference) considering the error of assay, it is unclear whether there was a true interference interaction in these combinations. Similarly, when combinations of Malian total IgGs and VAC063 total IgGs were examined, of 30 conditions (10 Malian total IgGs with 3 VAC063 IgGs), 3, 26, 0, and 1 combination showed synergistic, additive, subadditive, and interference interactions, respectively (in the final combination, there was only a 2%GIA difference between the mixture and the VAC063 IgG tested alone). Assuming *in vitro* GIA activity correlates with *in vivo* outcome in malaria-exposed populations, as has been shown in an *Aotus* monkey model and CHMI in the VAC063 trial, the lack of interference is promising for RH5 vaccine prospects and encourages further investigation of
RH5 vaccines in endemic areas. Indeed, results from the first phase Ib trial of an RH5-based vaccine in Tanzanian adults, children, and infants are awaited and will provide insight (ClinicalTrials.gov: NCT03435874).

In this study, we screened serum samples collected from 405 Malians at the peak of the malaria transmission season for reactivity against RH5 complex proteins in hopes of generating several RH5-, Ripr-, and CyRPA-specific IgG pools for experiments. However, antibody levels were too low to isolate Ripr- and CyRPA-specific IgGs. Similar to RH5,6,11,31,32 antibody titers to Ripr3 and CyRPA32–34 were previously reported to be low compared with other blood-stage antigens. Therefore, the low titers observed in this study are not surprising, but this study again highlights difficulties in studying infection-induced RH5-, Ripr-, and CyRPA-specific IgGs unless a much larger volume of serum is collected. When humans were immunized with a recombinant RH5 protein, vaccinated individuals demonstrated ~170-fold higher median EU than malaria-exposed individuals, indicating that the RH5 antigen is immunogenic in humans when properly presented (VAC057 and this study).

Human RH5-specific IgGs from Senegalese35 and Malians (in a different cohort from this study)36 have shown GIA activity in previous studies, but only one RH5-specific IgG pool was examined in each study. Therefore, it was not clear whether there is any difference in the characteristics of different RH5-specific IgGs. In this study, multiple RH5-specific IgG pools from individuals who were naturally infected (Malian IgGs) or vaccinated (VAC063 IgGs) were evaluated and directly compared. Of the two Malian RH5-specific IgGs (the blue and red filled triangles in Figure 3) that could be tested with >1,000 EU in GIA (a level expected to give greater than a background level of %GIA based on the VAC063 total and RH5-specific IgGs’ activity), one IgG showed no GIA activity (blue triangle) and the other showed a predicted level of %GIA (red triangle). In general, the Malian RH5-specific IgGs had lower avidity and bound less to RH5ΔNL (RH5 lacking the N terminus and disordered loop) and the RH5 complex but more to RH5NL and failed to show GIA activity at the expected concentration. In contrast, a higher level of RH5ΔNL binding was exhibited by the GIA-active second-highest-titer Malian IgG. However, when mice and rabbits were immunized with the N terminus of RH5, they produced GIA-active antibodies.30,36 Concerning binding to the RH5 complex, it is theoretically plausible that RH5 antibodies that bind sites exposed on the RH5 complex may have a longer time to inhibit the invasion process than RH5 antibodies that only recognize epitopes on RH5 that are covered by CyRPA in the complex; however, conflicting results have been published in this regard.16,24,37 Because only two Malian RH5-specific IgGs could be tested at a high-enough concentration, and the five VAC063 RH5-specific IgGs with strong GIA...
activity recognized RH5ΔNL, RH5Nt, and RH5 complex proteins relatively homogeneously, it is still an open question whether the ELISA results on binding characteristics can help explain the lack of GIA activity observed in the highest titer Malian RH5-specific IgG.

Combination GIAs with RH5 antibodies (either mAbs or pAbs) have been performed in many studies, but the terminology of additive and synergistic needs to be interpreted carefully. Bliss’s and/or Loewe’s definitions of additivity have been used in many studies, whereas other studies used neither definition. Bliss and Loewe additivity (and synergy) have different definitions, and both have advantages and disadvantages (a detailed mathematical discussion can be found elsewhere). Bliss additivity can be determined by testing a minimum of three experimental conditions (e.g., antibody A alone at one concentration, antibody B alone at one concentration, and a mixture of the two), but this definition carries a risk of self-synergy or self-antagonism (as described in detail previously). Loewe’s definition avoids the self-synergy issue. However, to determine Loewe additivity/synergy, multiple combination GIAs are required for each antibody mixture, because each of the two antibodies must be tested at multiple concentrations. Because limited amounts of human IgGs (especially RH5-specific IgGs) were available in this study, we designed our study to determine the interactions based on Bliss’s definition.

The recent discovery of a subset of antibodies that potentiate the activity of neutralizing merozoite antibodies opens up the possibility of increasing the protection conferred by a vaccine. These non-neutralizing, potentiating RH5 mAbs boosted the activity not only of neutralizing RH5 antibodies but also of pAbs from rabbits and rats immunized with other merozoite proteins, including RH4, CyRPA, Ripr, and AMA1, but not MSP1.18 In exploring the interaction between vaccine-induced and naturally acquired antimalarial antibodies. Most importantly, 10 of 11 Malian RH5-depleted IgGs and 9 of 10 Malian total IgGs did not display a detectable level of interference (i.e., a combination showing lower %GIA than either antibody alone) with any of the neutralizing RH5 antibodies tested (either mAbs or pAbs). This is in contrast to the interaction of AMA1-depleted Malian IgGs with neutralizing AMA1 antibodies. Assuming GIA activity correlates with in vivo outcome (as has been shown in Aotus monkey studies and human CHMI), this study suggests that antibody responses to an RH5 vaccine may combine independently (additively) with pre-existing GIA responses, giving a better outcome than vaccine alone and thus performing better than AMA1 vaccines in malaria-endemic areas. These results support further investigation of RH5 vaccines in target populations.

**Limitations of study**

The amount of each RH5-specific IgG pool was limited (each RH5-specific IgG pool was purified from 10–15 mL of serum); therefore, some experiments could not be performed (e.g., GIA at higher concentrations and IgG subclass determination) with these samples. We did not investigate the mechanism of synergy (with neutralizing RH5 mAbs) or antagonism (with VAC063 pooled IgGs), because only a minor proportion of Malian IgGs demonstrated such synergistic or antagonistic interactions, meaning we had a limited volume of material with which to investigate the mechanism. There is a risk of misclassification for the interactions (additive, synergistic, or antagonistic). As shown in the Supplemental information tables, there was a considerable level of inter-assay variation in %GIA values, whereas the variation between technical replicates on the same plate was relatively small, as measured by the percentage of the coefficient of variation (mean = 2.5, standard deviation = 2.5, n = 466 conditions). To assess the interaction effect, we opted to use DfB values instead of raw %GIA values, because the inter-assay
variation in DFB was comparatively smaller (Figure S5; Pearson correlation coefficient r from two assays was >0.83, p < 0.001 for all three datasets). In addition, the cutoff value of ±10 to define synergy or antagonism is somewhat arbitrary. For example, if the average DFB value is ~5, the antibody combination might have a weak but true antagonistic interaction, whereas it was labeled as an additive interaction in this study (drawing the conclusion that the two antibodies work independently). Nonetheless, we believe such a small effect would have a minimal biological impact. We performed all GIAs with a single strain of \textit{P. falciparum}, 3D7. Although RH5 vaccination of animals\textsuperscript{11,13,15} and humans\textsuperscript{17} induced strain-transcending antibodies, as judged by GIA, further study is required to confirm whether the generally additive interactions observed in the current study hold true for other strains of parasites. Finally, it is difficult to predict complicated immune responses \textit{in vivo} from these \textit{in vitro} experiments. For example, pre-existing immunity in the target population may alter the quality and quantity of anti-RH5 antibodies induced by vaccination. Only clinical trials in the target population can prove or disprove the efficacy of vaccine.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Malian cohort
  - RH5 human clinical trial (VAC063 trial)
- **METHOD DETAILS**
  - Recombinant proteins and monoclonal antibodies (mAbs)
  - Total and RH5-specific IgG purification
  - ELISA
  - GIA
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **ADDITIONAL RESOURCES**

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2021.100326.

**ACKNOWLEDGMENTS**

We thank all volunteers and the parents and guardians of children who participated in the Mali cohort study and VAC063 phase I/IIa trial; Seidina Diakite and Karim Traore for their contributions to the Mali cohort study; and the VAC063 clinical trial study team. The study was supported by the intramural program of the National Institute of Allergy and Infectious Diseases /NIH, and GIAs were partially supported by the U.S. Agency for International Development (USAID). D.G.W.A. held a UK Medical Research Council iCASE PhD Studentship (MR/K017632/1); S.J.D. is a Jenner investigator, a Lister Institute research prize fellow, and a Wellcome Trust senior fellow (106917/Z/15/Z). This work was also supported in part by the European Union’s Horizon 2020 research and innovation programme under a grant agreement for OptiMalVax (733273). The VAC063 clinical trial was funded by the Office of Infectious Diseases, Bureau for Global Health, USAID, under the terms of the Malaria Vaccine Development Program (MVDP) (AID-OAA-C-15-00071), for which Leidos Inc. is the prime contractor. The opinions expressed herein are those of the authors and do not necessarily reflect the views of USAID. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**AUTHOR CONTRIBUTIONS**

A.C.W., K.M., and C.A.L. designed the study; M.D., A.M.M., S.E.S., J.R.B., and S.J.D. coordinated and carried out the Malian cohort trial; D.P., D.G.W.A., and L.D.W.K. produced recombinant proteins and mAbs; A.C.W., A.D., and A.S.H. carried out laboratory procedures; A.C.W. and K.M. performed data analyses and prepared the initial draft of the manuscript; and S.J.D. and C.A.L. performed critical review and revision of the manuscript.

**DECLARATION OF INTERESTS**

D.G.W.A. and S.J.D. are named inventors on patent applications relating to RH5 vaccines and/or antibodies. A.M.M. has an immediate family member who is an inventor on patents relating to RH5 vaccines and/or antibodies. The authors declare no other competing interests.

Received: January 11, 2021
Revised: May 3, 2021
Accepted: June 4, 2021
Published: June 21, 2021

**REFERENCES**

1. World Health Organization (2020). World malaria report 2019 (World Health Organization).
2. Crosnier, C., Bustamante, L.Y., Bartholdson, S.J., Bei, A.K., Theron, M., Uchikawa, M., Mboup, S., Ndir, O., Kwiatkowski, D.P., Duraiasingh, M.T., et al. (2011). Basigin is a receptor essential for erythrocyte invasion by \textit{Plasmodium falciparum}. Nature 480, 534–537.
3. Wong, W., Huang, R., Menant, S., Hong, C., Sandow, J.J., Birkinshaw, R.W., Healer, J., Hodder, A.N., Kanjee, U., Tonkin, C.J., et al. (2019). Structure of \textit{Plasmodium falciparum} Rhs-CyRPA-Ripr invasion complex. Nature 565, 118–121.
4. Volz, J.C., Yap, A., Sisquella, X., Thompson, J.K., Lim, N.T., Whitehead, L.W., Chen, L., Lampe, M., Tham, W.H., Wilson, D., et al. (2016). Essential role of the PRH5/PRrip/CyRPA complex during \textit{Plasmodium falciparum} invasion of erythrocytes. Cell Host Microbe 20, 60–71.
5. Tran, T.M., Ongoiha, A., Courson, J., Crosnier, C., Diouf, A., Huang, C.Y., Li, S., Doumbo, S., Doumtabe, D., Kone, Y., et al. (2014). Naturally acquired antibodies specific for \textit{Plasmodium falciparum} reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J. Infect. Dis. 209, 789–798.
6. Richards, J.S., Arumugam, T.U., Reiling, L., Healer, J., Hodder, A.N., Fowkes, F.J., Cross, N., Langer, C., Takeo, S., Uboldi, A.D., et al. (2013). Identification and prioritization of merozoite antigens as targets of protective human immunity to \textit{Plasmodium falciparum} malaria for vaccine and biomarker development. J. Immunol. 191, 795–809.
7. Chiu, C.Y., Healer, J., Thompson, J.K., Chen, L., Kaul, A., Savergave, L., Raghuwanshi, A., Li Wai Suen, C.S., Siba, P.M., Schofield, L., et al. (2014). Association of antibodies to \textit{Plasmodium falciparum} reticulocyte binding protein homolog 5 with protection from clinical malaria. Front. Microbiol. 5, 314.
8. Weaver, R., Reiling, L., Feng, G., Drew, D.R., Mueller, I., Siba, P.M., Tsu- boi, T., Richards, J.S., Fowkes, F.J.I., and Beeson, J.G. (2016). The association between naturally acquired IgG subclass specific antibodies to the
PIRH5 invasion complex and protection from Plasmodium falciparum malaria. Sci. Rep. 6, 33094.
9. Douglas, A.D., Baldeviano, G.C., Lucas, C.M., Lugo-Roman, L.A., Crosnier, C., Bartholdson, S.J., Diouf, A., Miura, K., Lambert, L.E., Ventocilla, J.A., et al. (2015). A PIRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell Host Microbe 17, 130–139.
10. Douglas, A.D., Baldeviano, G.C., Jin, J., Miura, K., Diouf, A., Zenonos, Z.A., Ventocilla, J.A., Silk, S.E., Marshall, J.M., Alaine, D.G.W., et al. (2019). A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-primate nates. Nat. Commun. 10, 5513.

11. Douglas, A.D., Williams, A.R., Illingworth, J.J., Kamuyu, G., Biswas, S., Goodman, A.L., Wyllie, D.H., Crosnier, C., Miura, K., Wright, G.J., et al. (2011). The blood-stage malaria antigen PIRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2, 601.
12. Ord, R.L., Rodriguez, M., Yamasaki, T., Takeo, S., Tsuboi, T., and Lobo, C.A. (2012). Targeting sialic acid dependent and independent pathways of invasion in Plasmodium falciparum. PLoS ONE 7, e30251.
13. Williams, A.R., Douglas, A.D., Miura, K., Illingworth, J.J., Choudhary, P., Munungi, L.M., Furze, J.M., Diouf, A., Miotto, O., Crosnier, C., et al. (2012). Enhancing blockade of Plasmodium falciparum erythrocyte invasion assessing combinations of antibodies against PIRH5 and other merozoite antigens. PLoS Pathog. 8, e1002991.
14. Bustamante, L.Y., Bartholdson, S.J., Crosnier, C., Campos, M.G., Wana-guru, M., Nguo, C., Kwiartkowski, D.P., Wright, G.J., and Rayner, J.C. (2013). A full-length recombinant Plasmodium falciparum PIRH5 protein induces inhibitory antibodies that are effective against common PIRH5 genetic variants. Vaccine 31, 373–379.
15. Reddy, K.S., Pandey, A.K., Singh, H., Sahar, T., Emmanuel, A., Chitnis, C.E., Chauhan, V.S., and Gaur, D. (2014). Bacterially expressed full-length recombinant Plasmodium falciparum PIRH5 protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies. Infect. Immun. 82, 152–164.
16. Healer, J., Wong, W., Thompson, J.K., He, W., Birkinshaw, R.W., Miura, K., Long, C.A., Soroka, V., Sægard, T.M.M., Jørgensen, T., et al. (2019). Neutralizing antibodies block the function of RH5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes. Cell Microbiol. 21, e13302.
17. Payne, R.O., Silk, S.E., Elias, S.C., Miura, K., Diouf, A., Galaway, F., de Graaf, H., Brendish, N.J., Poulton, I.D., Griffiths, O.J., et al. (2017). Human vaccination against RH5 induces neutralizing alantimalarial antibodies that inhibit RH5 invasion complex interactions. JCI Insight 2, 98518.
18. Alaine, D.G.W., Quinkert, D., Wana-guru, M., Ogada, E., McDade, B., Rayner, J.C., and Marsh, K. (2014). New antigens for a multicomponent blood-stage malaria vaccine. Sci. Transl. Med. 6, 247ra102.
19. Partey, F.D., Castberg, F.C., Sarbah, E.W.,Silk, S.E., Awandare, G.A., Draper, S.J., Opoku, N., Kweku, M., Ofior, M.F., Hvid, L., and Barford, L. (2018). Kinetics of antibody responses to PIRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. PLoS ONE 13, e0198371.
20. Dreyer, A.M., Matile, H., Papastogiannidcs, P., Kamber, J., Favuzza, P., Voss, T.S., Wittlin, S., and Plaschke, G. (2012). Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidacy malaria vaccine antigen. J. Immunol. 188, 6225–6237.
21. Patil, A., Kolhe, A., and Duraisingh, M.T. (2013). Plasmodium falciparum merozoite surface antigen, PIRH5, elicits detectable levels of invasion-inhibiting antibodies in humans. J. Infect. Dis. 208, 1679–1687.
22. Minassian, A.M., Silk, S.E., Barrett, J.R., Nielsen, C.M., Miura, K., Diouf, A., Loos, C., Fallon, J.K., Michell, A.R., White, M.T., et al. (2021). Reduced blood-stage malaria growth and immune correlates in humans following RHI Vaccination. Med. 2, 326.
23. Thera, M.A., Dourno, O.K., Cuilinbaly, D., Laurens, M.B., Outtara, A., Kone, A.K., Guindo, A.B., Traore, K., Traore, I., Kouriba, B., et al. (2011). A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004–1013.
24. Chen, L., Xu, Y., Wang, W., Thompson, J.K., Healer, J., Goddard-Boger, E.D., Lawrence, M.C., and Cowman, A.F. (2017). Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA. eLife 6, e21347.
25. Reddy, K.S., Amlabu, E., Pandey, A.K., Mitra, P., Chauhan, V.S., and Gaur, D. (2015). Multiprotein complex between the GPI-anchored CyRPA with PIRH5 and PirRip is crucial for Plasmodium falciparum erythrocyte invasion. Proc. Natl. Acad. Sci. USA 112, 1179–1184.
39. Favuzza, P., Guffart, E., Tamborini, M., Scherer, B., Dreger, A.M., Rufer, A.C., Erny, J., Hoernschemeyer, J., Thoma, R., Schmid, G., et al. (2017). Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody. eLife 6, e20383.

40. Illingworth, J.J., Alanine, D.G., Brown, R., Marshall, J.M., Bartlett, H.E., Silk, S.E., Labbé, G.M., Quinkert, D., Cho, J.S., Wendler, J.P., et al. (2019). Functional comparison of blood-stage Plasmodium falciparum malaria vaccine candidate antigens. Front. Immunol. 10, 1254.

41. Azasi, Y., Gallagher, S.K., Diouf, A., Dabbs, R.A., Jin, J., Mian, S.Y., Narum, D.L., Long, C.A., Gaur, D., Draper, S.J., et al. (2020). Bliss’ and Loewe’s additive and synergistic effects in Plasmodium falciparum growth inhibition by AMA1-RON2L, RH5, RIPR and CyRPA antibody combinations. Sci. Rep. 10, 11802.

42. Rijal, P., Elias, S.C., Machado, S.R., Xiao, J., Schimanski, L., O’Dowd, V., Baker, T., Barry, E., Mendelsohn, S.C., Cherry, C.J., et al. (2019). Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Rep. 27, 172-186.e7.

43. Miura, K., Orcutt, A.C., Muratova, O.V., Miller, L.H., Saul, A., and Long, C.A. (2008). Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26, 193-200.

44. Malkin, E.M., Diemert, D.J., McArthur, J.H., Perreault, J.R., Miles, A.P., Giersing, B.K., Mullen, G.E., Orcutt, A., Muratova, O., Awkal, M., et al. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73, 3677-3685.

45. Bliss, C.I. (1939). The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615.
STAR METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| R5.010, R5.011, R5.014, R5.004, R5.008 and R5.016 | Simon J. Draper, Oxford University: Alanine et al. | N/A |
| EBL040              | Simon J. Draper, Oxford University: Rijal et al. | N/A |
| Alkaline Phosphatase Labeled Goat anti-Human IgG (H+L) | Kirkegaard & Perry Labs | Cat # 075-1006 |
| Biological samples  |        |            |
| Malian sera         | Carole A Long, NIAID: Adomakko-Ankomah et al. | N/A |
| VAC063 sera         | Simon J. Draper, Oxford University, Clinicaltrials.gov: NCT02927145 | N/A |
| Chemicals, peptides, and recombinant proteins | | |
| RH5.1               | Simon J. Draper, Oxford University: Jin et al. | N/A |
| Full-length Ripr    | Simon J. Draper, Oxford University: Alanine et al. | N/A |
| Full-length CyRPA   | Simon J. Draper, Oxford University: Alanine et al. | N/A |
| RH5ΔNL              | Simon J. Draper, Oxford University: Alanine et al. | N/A |
| RH5Nt               | Simon J. Draper, Oxford University: Galaway et al. | N/A |
| NHS-activated Sepharose 4 Fast Flow | Cytiva | Cat# 17090601 |
| Experimental models: Organisms/strains | | |
| P. falciparum 3D7    | Carole A Long, NIAID | N/A |
| P. falciparum FVO   | Carole A Long, NIAID | N/A |
| Software and algorithms | | |
| GraphPad Prism version 8 | GraphPad (https://www.graphpad.com/) | N/A |

RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kazutoyo Miura (kmiura@niaid.nih.gov).

Materials availability
There are restrictions to the availability of the human sera described in this manuscript due to ethical approvals for the studies. Requests directed to the Lead Contact will be considered on an individual basis.

Data and code availability
The published article includes all datasets generated or analyzed during this study, and no code was generated in this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Malian cohort
Details of the study site and cohort have been described previously. Briefly, the study was conducted with 500 individuals aged 1-65 living in the village of Kenieroba, Mali, an area of high malaria transmission with a rainy season from June to December. Blood samples were collected from participants every other week from June 2013 to May 2014. Detection of infection with P. falciparum was performed using a species-specific nested PCR, as described. If participants presented with malaria symptoms during a scheduled visit or by self-referral to the health center, parasitemia was measured by microscopy, as described. A malaria case was defined as an axillary temperature > 37.5°C and asexual parasite density > 5000/μL.

From 405 volunteers, 2-5 mL of serum were collected at the peak of the malaria transmission season (October 2013) and used for the current study. This study received approval from the Institutional Review Board of the National Institute of Allergy and Infectious Diseases and the Ethics Committee of the Faculty of Medicine, Pharmacy, and Odontostomatology, University of Bamako. Written
informed consent was obtained from study participants or the parents or guardians of children aged < 18 years, and the trial is registered at Clinicaltrials.gov: NCT01829737.

**RH5 human clinical trial (VAC063 trial)**

The details of the RH5.1/AS01b vaccine trial (VAC063 trial) were described. In brief, the VAC063 trial was an open-label, non-randomized dose escalation Phase IIa trial using the RH5.1 protein (full-length recombinant RH5 protein based on the 3D7 sequence) formulated in GSK’s adjuvant system AS01b. Healthy malaria-naïve UK adults from 18 to 50 years old were immunized with 2, 10 or 50 μg of RH5.1 protein on days 0, 28 and 56, or days 0, 28 and 182. The trial was registered on Clinicaltrials.gov: NCT02927145, received ethical approval from the UK NHS Research Ethics Service (Oxfordshire Research Ethics Committee A, Ref 16/SC/0345), and was approved by the UK Medicines and Healthcare Products Regulatory Agency (Ref 21584/0362/001-0001). Written informed consent was obtained from study participants. For this study, 11 total IgG pools were made from the purified total IgGs of 59 vaccinees based on their RH5 antibody levels and available volumes, irrespective of immunization group or study day (samples used ranged from day 70 to 366 from Group 1, 2 or 6). Each pool consisted of 4 to 25 individual total IgGs.

**METHOD DETAILS**

**Recombinant proteins and monoclonal antibodies (mAbs)**

RH5.1 (amino acid, aa E26 to Q526), full-length Ripr (aa D21 to N1086), full-length CyRPA (aa D29 to E362), RH5NL (aa K140 to K247 and N297 to Q526), and RH5Nt (aa F25 to K140) were produced and purified as described previously. In brief, all constructs were made based on the 3D7 sequence of *P. falciparum* with mutations to delete N-linked glycosylation using *Drosophila* S2 (RH5.1, Ripr, RH5NL) or Exp2i93F HEK (CyRPA, RH5Nt) expression systems. Recombinant proteins were purified from the cell supernatant using Capture Select C-tag (RH5.1, RH5NL RIPR, CyRPA) or immobilized metal ion (RH5Nt) affinity chromatography, followed by size exclusion chromatography (SEC) into TBS (20 mM Tris, 150 mM NaCl) pH 7.4. The RH5 complex was reconstituted *in vitro* by incubating equimolar concentrations of RH5.1, CyRPA and Ripr proteins at 4°C for 1h before purifying by SEC. (Pulido D et al., in preparation).

The human RH5 mAbs used in the combination GIA were all cloned as human IgG1 and isolated from vaccinated participants in the VAC057 trial, in which they were immunized with replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA), both encoding full-length RH5. Detailed descriptions of the mAbs have been reported previously. Several non-neutralizing but potentiating RH5 mAbs (R5.010, R5.011, and R5.014) as well as neutralizing RH5 mAbs (R5.004, R5.008, and R5.016) were used in this study. As a negative control, a human Ebola virus mAb (EBL040) was used.

**Total and RH5-specific IgG purification**

Using 138 individual Malian serum samples, 23 serum pools were generated (each pool consisted of 5 to 12 individual sera), and total IgGs were purified using Protein G columns. RH5-specific IgGs were purified from the total IgG pools by RH5 affinity purification using columns with RH5.1-coated beads. The flow-through fraction was also collected and represents RH5-depleted IgG. The methods for purifying RH5-specific and RH5-depleted IgGs were described previously. RH5-specific IgGs could only be purified from eight of the 23 pooled total IgGs (RH5 antibody levels in the remaining 15 total IgG samples were too low for successful purification of RH5-specific IgGs). Similarly, RH5-specific IgGs were affinity purified from 8 (out of 11) pooled VAC063 total IgGs. Additional non-pooled total IgGs were also prepared from 24 individual Malian sera. As a negative control, total IgGs were purified from the serum of malaria-naïve U.S. adults purchased from Interstate Blood Bank (Memphis, TN). All total, RH5-specific, and RH5-depleted IgGs were heat inactivated, pre-adsorbed with human erythrocytes, dialyzed against RPMI 1640, and sterilized with a 0.22 μm filter for use in GIA.

**ELISA**

As a preliminary ELISA screen for the Malian sera, the 405 serum samples were tested at a 1:200 dilution against RH5.1, Ripr and CyRPA proteins to identify seropositive samples. The OD cut-off for positivity was defined as any OD above the mean + 2 standard deviations of 12 malaria-naïve U.S. sera. ELISA units (EU) against RH5.1 were determined for all seropositive serum samples using the standardized ELISA methodology as described previously with a small modification: each sample was tested in duplicate, not triplicate.

403 of the 405 Malian sera were also tested by ELISA against *Plasmodium falciparum* FVO blood-stage parasite lysate. Two serum samples were not tested due to limited volume. Infected erythrocytes (majority late stage trophozoites) were lysed by saponin treatment and then sonicated in an ice bath. ELISA plates were coated with the lysate at approximately 5 × 10⁴ parasites/well, and the standardized ELISA was performed as described above.

RH5.1 titers in total, RH5-specific and RH5-depleted IgGs were measured using the standardized ELISA, as described above. RH5-specific antibodies were also tested for binding to two truncated RH5 proteins (RH5ΔNL and RH5Nt) as well as the recombinant RH5 complex (RCR). Each sample was diluted to target an OD of 1.0 against RH5.1 and tested against both RH5.1 and RH5ΔNL, RH5Nt or RCR on the same plate. The results are reported as an OD ratio between RH5ΔNL and RH5.1, RH5Nt and RH5.1, or RCR and RH5.1.
An avidity ELISA was also performed using the RH5-specific IgGs. Each sample was diluted to target an OD of approximately 2.0 against RH5.1 protein, and the ELISA was run as usual with an added 20-minute incubation with urea in 1X TBS (urea concentrations ranging from 1 to 6 M) following the primary antibody incubation. The concentration of urea resulting in a 20% reduction in EU (IC20) was calculated using linear regression.

**GIA**

GIAs assessing the ability of antibody samples to inhibit parasite growth were performed with the 3D7 clone of *P. falciparum* as described previously.44 For the GIA with single IgGs, the samples were diluted in RPMI to achieve the indicated concentration in RH5.1 EU or mg/ml. The total and RH5-specific IgGs from the VAC063 trial were tested at serial dilutions.

Mixtures of antibodies were assessed in combination GIAs. For the combination GIAs, the RH5-specific antibodies from Malian total IgGs were tested at the highest concentration possible. Malian pooled total IgGs, RH5-depleted IgGs and individual total IgGs were tested at 10 mg/ml unless they showed > 50% inhibition at this concentration, in which case they were tested at 2.5 mg/ml, or at 1.25 mg/ml if they still showed > 50% inhibition at 2.5 mg/ml. The pooled VAC063 total IgGs were tested at 1 mg/ml (mixture with RH5 mAbs), 0.625 mg/ml (with Malian RH5-depleted IgGs, Figures 5A and 5B), or 1.25 mg/ml (with Malian total IgGs, Figure 5D), while the VAC063 RH5-specific IgGs were diluted to target ~60% inhibition in GIA (%GIA). Three non-neutralizing, but potentiating, RH5 mAbs (R5.010, R5.011, and R5.014) were tested at 300 mg/ml, as described previously.18 Three neutralizing RH5 mAbs (R5.004, R5.008 and R5.016) were tested at 50, 125 and 19 mg/ml to target ~50%–60%GIA. A human Ebola virus mAb was used as the negative control mAb, and a U.S. total IgG was used as the negative control total IgG. The details of mixture conditions and the original %GIA value for each condition are shown in Tables S1, S2, S3, S4, and S5. Figure 4A shows GIA results from a single assay, and Figures 4B and 5 show average results from two independent assays.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Predicted % inhibition values for antibody combinations were calculated using the formula for Bliss additivity, originally developed to assess the toxicity of poisons in combination.45 The following formula, specific for antibody combinations in GIA, was used in the current study:

\[
\%GIA_{A \cdot B} = \left[1 - (1 - \%GIA_A) \cdot (1 - \%GIA_B)\right] \cdot 100
\]

where \(\%GIA_{A \cdot B}\) is the %GIA of a combination of antibody A and antibody B, \(\%GIA_A\) is the %GIA when antibody A is tested alone, and \(\%GIA_B\) is antibody B alone. The difference between Bliss predicted %GIA and the observed %GIA in the mixture is denoted as “Delta from Bliss (DfB)” in this manuscript. We define additive interactions as those that give observed %GIA values within 10% on either side of the value predicted by Bliss (i.e., DfB is ± 10). If the observed %GIA is 10% or more greater than the value predicted by Bliss additivity (i.e., DfB is ≥ 10), the interaction is considered “synergistic.” If the observed %GIA is 10% or more less than predicted (i.e., DfB is ≤ −10), the interaction is considered “antagonistic.” The “antagonistic” interaction is further categorized into “sub-additive” and “interference” interactions. The former means the %GIA in the antibody combination is higher than the %GIA of either antibody alone, and the latter denotes the combination shows lower %GIA than either antibody alone. Unless otherwise mentioned, average DfB values from two independent assays were utilized to judge the “additive,” “synergistic” or “antagonistic” (“sub-additive” and “interference”) interactions.

To determine the impact of age category on seropositivity among the individual Malian sera, a chi-square test for trend was used. A Spearman rank test was used for assessing correlations, a Fisher’s exact test for comparing proportions of samples between two groups, and a Mann-Whitney test for comparing means of two groups. All data analyses were performed using GraphPad Prism version 8 (GraphPad Software Inc.).

**ADDITIONAL RESOURCES**

The Mali and UK trials are registered as Clinicaltrials.gov: NCT01829737 and NCT02927145, respectively.